These data support a mechanism of HER3/HER2 activation and migration by ASPN in prostate cancer, thereby highlighting HER2 and HER3 as potential therapeutic vulnerabilities in metastatic prostate cancer. Here, ERBB2 is linked to prostate carcinoma.